Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
In addition to our HBV Assets, we are developing a pipeline of Oncology, Anti-viral and Metabolic Programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.
May 3, 2016
Arbutus Expands HBV Pipeline
May 4, 2016 at 1:30 PM PT
Arbutus Biopharma 2016 First Quarter Financial Results